Studying Treatments in patients receiving androgen deprivation therapy (ADT) and androgen receptor signalling inhibitors (ARSI) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2).

Research summary

This is a platform trial testing the addition of experimental treatments to standard of care (SoC) with three randomised controlled trials called research comparisons. The platform design allows the addition of other research treatments into the structure following protocol amendment. The primary objectives of each comparison are to test whether efficacy outcomes can be improved by the addition of the research treatments to SoC in men with metastatic prostate cancer and starting long-term androgen deprivation therapy. Key secondary objectives of each comparison are to test the toxicity and compliance with the research arms,whether Quality of Life is altered with the addition of research therapies and the cost and resource use (including EQ-5D-5L to calculate the incremental cost-effectiveness ratio of comparisons or the net monetary benefits by arm,as appropriate).

Principal Investigator

Philip Charlton

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1006437